Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes - PubMed (original) (raw)
Comparative Study
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
Kamel Mohammedi et al. Cardiovasc Diabetol. 2017.
Abstract
Background: Microvascular disease is associated with a high risk of macrovascular events in patients with type 2 diabetes, but the impact of macrovascular disease on the risk of microvascular events remains unknown. We sought to evaluate the respective effects of prior microvascular and macrovascular disease on the risk of major outcomes, including microvascular events, in these patients.
Methods: Participants in the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation (ADVANCE) trial (n = 11,140) and the ADVANCE-ON post-trial study (n = 8494) were categorized into 4 groups at baseline: dual absence of microvascular or macrovascular disease (n = 6789), presence of microvascular disease alone (n = 761), macrovascular disease alone (n = 3196), and both (n = 394). Outcomes were all-cause mortality, major macrovascular events (MACE), and major clinical microvascular events.
Results: All-cause mortality, MACE, and major clinical microvascular events occurred in 2265 (20%), 2166 (19%), and 807 (7%) participants respectively, during a median follow-up of 9.9 (inter-quartile interval 5.6-10.9) years. The adjusted hazard ratios [95% CI] of death, MACE, and major clinical microvascular events were each greater in patients with baseline microvascular disease (1.43 [1.20-1.71], 1.64 [1.37-1.97], and 4.74 [3.86-5.82], respectively), macrovascular disease (1.43 [1.30-1.57], 2.04 [1.86-2.25], and 1.26 [1.06-1.51]) or both (2.01 [1.65-2.45], 2.92 [2.40-3.55], and 6.30 [4.93-8.06]) compared with those without these conditions. No interaction was observed between baseline microvascular and macrovascular disease for these events. The addition of microvascular disease (change in c-statistic [95% CI] 0.005 [0.002-0.008], p = 0.02) or macrovascular disease (0.005 [0.002-0.007], p < 0.0001) considered separately or together (0.011 [0.007-0.014], p < 0.0001) improved the discrimination and the classification (integrated discrimination improvement (IDI): 0.013 [0.010-0.016], p < 0.001; net reclassification improvement (NRI): 0.021 [0.011-0.032], p < 0.001) of the risk of all-cause mortality. Microvascular disease improved discrimination (0.009 [0.003-0.014]) and classification (IDI: 0.008 [0.006-0.010]; NRI: 0.011 [0.001-0.020]) of MACE. Baseline macrovascular disease modestly enhanced IDI (0.002 [0.001-0.002]) and NRI (0.041 [0.002-0.087]), but not discrimination, of major clinical microvascular events.
Conclusions: Microvascular and macrovascular disease are independently associated with the 10-year risk of death, MACE, and major clinical microvascular events in patients with type 2 diabetes. The coexistence of these conditions was associated with the highest risks.
Keywords: Macrovascular disease; Microvascular disease; Mortality; Type 2 diabetes.
Figures
Fig. 1
Cumulative incidence of outcomes during follow-up according to status of microvascular and macrovascular disease at baseline. a All-cause mortality. b Major macrovascular events. c Major clinical microvascular disease (p < 0.0001 for all). Black line absence of both macrovascular and microvascular disease. Blue line presence of microvascular disease alone. Green line presence of macrovascular disease alone. Red line presence of both microvascular and macrovascular disease
Similar articles
- Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Hirakawa Y, Arima H, Zoungas S, Ninomiya T, Cooper M, Hamet P, Mancia G, Poulter N, Harrap S, Woodward M, Chalmers J. Hirakawa Y, et al. Diabetes Care. 2014 Aug;37(8):2359-65. doi: 10.2337/dc14-0199. Epub 2014 May 8. Diabetes Care. 2014. PMID: 24812434 Clinical Trial. - Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial.
Tian J, Ohkuma T, Cooper M, Harrap S, Mancia G, Poulter N, Wang JG, Zoungas S, Woodward M, Chalmers J. Tian J, et al. Diabetes Care. 2020 Jun;43(6):1293-1299. doi: 10.2337/dc19-1817. Epub 2020 Mar 19. Diabetes Care. 2020. PMID: 32193249 Clinical Trial. - Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M; ADVANCE-ON Collaborative Group. Zoungas S, et al. N Engl J Med. 2014 Oct 9;371(15):1392-406. doi: 10.1056/NEJMoa1407963. Epub 2014 Sep 19. N Engl J Med. 2014. PMID: 25234206 Clinical Trial. - New insights from ADVANCE.
Chalmers J, Kengne AP, Joshi R, Perkovic V, Patel A. Chalmers J, et al. J Hypertens Suppl. 2007 Jun;25(1):S23-30. doi: 10.1097/01.hjh.0000271506.69949.46. J Hypertens Suppl. 2007. PMID: 17579315 Review. - What matters in ADVANCE and ADVANCE-ON.
Hamet P. Hamet P. Diabetes Obes Metab. 2012 Jan;14 Suppl 1:20-9. doi: 10.1111/j.1463-1326.2011.01509.x. Diabetes Obes Metab. 2012. PMID: 22118707 Review.
Cited by
- Determining the Best Noninvasive Test for Peripheral Arterial Disease Diagnosis to Predict Diabetic Foot Ulcer Healing in Patients Following Endovascular Revascularization.
Álvaro-Afonso FJ, García-Álvarez Y, García-Morales EA, Flores-Escobar S, De Benito-Fernández L, Alfayate-García J, Sánchez-Ríos JP, Puras-Mallagray E, Malo-Benages EJ, Ramírez-Ortega M, Redondo-López S, Cecilia-Matilla A, Lázaro-Martínez JL. Álvaro-Afonso FJ, et al. Healthcare (Basel). 2024 Aug 20;12(16):1664. doi: 10.3390/healthcare12161664. Healthcare (Basel). 2024. PMID: 39201221 Free PMC article. - A Study of the Prevalence of Diabetic Retinopathy in Patients With Ischemic Heart Disease and Diabetes Mellitus.
Radhakrishnan O, Goyal K, Vatkar V, Gandhi S, Agrawal T. Radhakrishnan O, et al. Cureus. 2024 Jul 20;16(7):e65005. doi: 10.7759/cureus.65005. eCollection 2024 Jul. Cureus. 2024. PMID: 39161485 Free PMC article. - Mediation effect of antithrombin III between chronic renal insufficiency and chronic coronary artery disease in T2DM patients.
Sun R, Jia J, Wang S, Wang Z, Wang C, Xu Y, Yuan Y. Sun R, et al. Endocrine. 2024 Jun;84(3):924-933. doi: 10.1007/s12020-023-03669-0. Epub 2024 Jan 8. Endocrine. 2024. PMID: 38190026 - Disease and Economic Burden of Poor Metabolic and Weight Control in Type 2 Diabetes in Spain: A Systematic Literature Review.
Pérez A, Redondo-Antón J, Romera I, Lizán L, Rubio-de Santos M, Díaz-Cerezo S, Orozco-Beltrán D. Pérez A, et al. Diabetes Ther. 2024 Feb;15(2):325-341. doi: 10.1007/s13300-023-01503-4. Epub 2023 Nov 22. Diabetes Ther. 2024. PMID: 37989829 Free PMC article. Review. - Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes.
Bansal S, Burman A, Tripathi AK. Bansal S, et al. World J Diabetes. 2023 Aug 15;14(8):1146-1162. doi: 10.4239/wjd.v14.i8.1146. World J Diabetes. 2023. PMID: 37664478 Free PMC article. Review.
References
- Cordero A, Lopez-Palop R, Carrillo P, Moreno-Arribas J, Bertomeu-Gonzalez V, Frutos A, Garcia-Carrilero M, Gunturiz C, Bertomeu-Martinez V. Comparison of long-term mortality for cardiac diseases in patients with versus without diabetes mellitus. Am J Cardiol. 2016;117(7):1088–1094. doi: 10.1016/j.amjcard.2015.12.057. - DOI - PubMed
- Bots SH, van der Graaf Y, Nathoe HM, de Borst GJ, Kappelle JL, Visseren FL, Westerink J. The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease. Cardiovasc Diabetol. 2016;15(1I):101. doi: 10.1186/s12933-016-0418-1. - DOI - PMC - PubMed
- Bramlage P, Gitt AK, Schneider S, Deeg E, Tschope D. Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control—results of the 2 year prospective DiaRegis follow-up. BMC Cardiovasc Disord. 2014;14:162. doi: 10.1186/1471-2261-14-162. - DOI - PMC - PubMed
- Kontopantelis E, Springate DA, Reeves D, Ashcroft DM, Rutter MK, Buchan I, Doran T. Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. Diabetologia. 2015;58(3I):505–518. doi: 10.1007/s00125-014-3473-8. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous